Feasibility of Magnetic Resonance Spectroscopy in Lung Cancer

NCT02497586 | Unknown

• 1 other identifier: GN15ON255
• Study Type: interventional
• Target: 15
• Locations: 0 countries
• Sites: N/A

Brief Summary

Lung cancer is commonly characterised either with a surgical procedure or by taking a tissue sample with a needle. Unfortunately, these invasive approaches may be unsafe in many patients with lung cancer, who often have co-existing illnesses such as emphysema. Magnetic resonance spectroscopy (MRS) is a type of scan which offers the possibility of assessing tumour function by measuring concentrations of chemicals (metabolites) within the abnormal tissue. It is a well-established technique in imaging brain cancers. It has also been more recently studied in assessing prostate, liver and heart. There has been very little exploration of the potential role of MRS in lung cancer. The proposed feasibility study will recruit 15 patients with proven lung cancer to undergo an MRS scan. The reliability of the technique for metabolite measurement will be determined by comparing repeated scans from the same region in the same tumour. Further scans from different regions in the same tumour, normal lung around the tumour and tumour regions in different patients will be used to look for any patterns in the cancer metabolites which may indicate avenues for potential future research.

Conditions

Lung Cancer

Outcome Measures

Primary Outcomes (1)

• Presence of metabolite peaks

  Presence of metabolite peaks in MR spectra obtained from lung tumours using a 3T MR system.

  Data collected on day 1

Secondary Outcomes (2)

• Reproducability of metabolite peaks

  Data collected on day 1

• Metabolite peak-clinical parameter colleration

  Data collected on day 1

Study Arms (1)

MRS

EXPERIMENTAL

Magnetic resonance spectroscopy (MRS) is a type of scan which offers the possibility of assessing tumour function by measuring concentrations of chemicals (metabolites) within the abnormal tissue. This is a prospective feasibility study, aiming to recruit 15 consecutive patients with lung cancer to undergo proton MRS. The feasibility and repeatability of the technique will be assessed by analysis of the MR spectra obtained.

Radiation: Magnetic resonance spectroscopy

Interventions

Magnetic resonance spectroscopy RADIATION

Magnetic resonance spectroscopy (MRS) is a type of scan which offers the possibility of assessing tumour function by measuring concentrations of chemicals (metabolites) within the abnormal tissue. It is a well-established technique in imaging brain cancers.

MRS

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• biopsy-confirmed small cell or non-small cell lung cancer
• solid intrapulmonary tumour of at least 3 cm in long and short axis diameters on transverse CT images
• ECOG performance status ≤ 2
• able to provide written informed consent and respond appropriately to verbal instructions for scan acquisition
• age 18 years or older

You may not qualify if:

• chemotherapy within the preceding 12 months
• previous radiotherapy to the tumour
• cardiac pacemaker/defibrillator, internal pacing wires, cerebral aneurysm clip, incompatible metallic heart valve replacements, other incompatible implants/prostheses, claustrophobia or other MRI contraindication
• history of metal entering the body or eye, unless residual metal in the affected area likely to cause harm has been adequately excluded by X-ray in the opinion of Dr Cowell or Dr Stobo
• intractable cough, inability to lie flat or other impediment to acquisition of breath-held MR images
• pregnancy

Sponsors & Collaborators

• NHS Greater Glasgow and Clyde: lead

Related Publications (1)

• Castillo M, Kwock L, Mukherji SK. Clinical applications of proton MR spectroscopy. AJNR Am J Neuroradiol. 1996 Jan;17(1):1-15. No abstract available.

  PMID: 8770242 BACKGROUND

MeSH Terms

Conditions

Lung Neoplasms

Interventions

Magnetic Resonance Spectroscopy

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Spectrum Analysis; Chemistry Techniques, Analytical; Investigative Techniques

Study Officials

• David B Stobo, Dr

  NHS Greater Glasgow and Clyde

  PRINCIPAL INVESTIGATOR

Central Study Contacts

David B Stobo, Dr

CONTACT

0141 452 3635; david.stobo2@ggc.scot.nhs.uk

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 15, 2015
• First Posted: July 14, 2015
• Study Start: August 1, 2015
• Primary Completion: July 1, 2016
• Study Completion: July 1, 2016
• Last Updated: July 14, 2015

Record last verified: 2015-07